Antibody Information
General Information of This Antibody
| Antibody ID | ANI0KHSLK |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | hL49_3x_Ala |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Melanotransferrin (MELTF) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
hL49_3x_Ala-ADC [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
8.00%
|
Moderate CD228 expression (CD228++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Melanoma | A2058 cells | CVCL_1059 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
65.00%
|
Low CD228 expression (CD228+) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Amelanotic melanoma | A-375 cells | CVCL_0132 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
72.00%
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-28 cells | CVCL_0526 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
80.00%
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | COLO 853 cells | CVCL_2003 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
84.00%
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Melanoma | IGR-37 cells | CVCL_2075 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) |
87.00%
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-5 cells | CVCL_0527 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.00 nM
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-28 cells | CVCL_0526 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
6.00 nM
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-5 cells | CVCL_0527 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
10.00 nM
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | COLO 853 cells | CVCL_2003 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
162 nM
|
Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Melanoma | IGR-37 cells | CVCL_2075 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 2000 nM | Moderate CD228 expression (CD228++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Melanoma | A2058 cells | CVCL_1059 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.32 uM
|
Low CD228 expression (CD228+) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Amelanotic melanoma | A-375 cells | CVCL_0132 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.